Hims and Hers同意停止销售复合Wegovy和Ozempic，并于2026年3月前转为品牌版本，结束了与诺和诺德的专利诉讼。 Hims & Hers agrees to stop selling compounded Wegovy and Ozempic, switching to branded versions by March 2026, ending a patent lawsuit with Novo Nordisk.

Hims and Hers与诺和诺德已和解专利诉讼，结束了Hims销售Wegovy和Ozempic复合配方的法律纠纷。 Hims & Hers and Novo Nordisk have settled their patent lawsuit, ending legal conflict over Hims’ sale of compounded versions of Wegovy and Ozempic. 根据该协议,Hims将停止推广和销售GLP-1复合药物,而是通过2026年3月开始的远程保健平台,提供有品牌的Wegovy和Ozempic版本。 Under the agreement, Hims will stop promoting and selling compounded GLP-1 drugs and will instead offer branded versions of Wegovy and Ozempic through its telehealth platform starting in March 2026. FDA威胁限制用于配制的成分，促成了此次解决。 The FDA’s threat to restrict ingredients used in compounding contributed to the resolution. Novo Nordisk撤销了诉讼,但保留重新提交的权利。 Novo Nordisk dropped its lawsuit but reserves the right to refile. Hims & Hers股价因消息上涨超过36%，诺和诺德股价上涨1.8%。 Hims & Hers shares rose over 36% on the news, while Novo Nordisk’s stock increased 1.8%.